240 related articles for article (PubMed ID: 24393588)
61. [Features of colorectal cancer with fecal-occult-blood tests--comparison with colorectal cancer with no screening].
Takemasa I; Kikkawa N; Yasui M; Nishisho I; Fujitani K; Mishima H; Hasuike Y; Kobayashi K
Gan To Kagaku Ryoho; 1998 Aug; 25(10):1514-8. PubMed ID: 9725042
[TBL] [Abstract][Full Text] [Related]
62. Impact of the faecal immunochemical test on colorectal cancer survival.
Gutierrez-Stampa MA; Aguilar V; Sarasqueta C; Cubiella J; Portillo I; Bujanda L
BMC Cancer; 2020 Jul; 20(1):616. PubMed ID: 32611328
[TBL] [Abstract][Full Text] [Related]
63. Stages of Adoption for Fecal Occult Blood Test and Colonoscopy Tests for Colorectal Cancer Screening in Korea.
Bui NC; Cho HN; Lee YY; Suh M; Park B; Jun JK; Kim Y; Choi KS
Cancer Res Treat; 2018 Apr; 50(2):416-427. PubMed ID: 28494531
[TBL] [Abstract][Full Text] [Related]
64. A comparison of tumour and host prognostic factors in screen-detected vs nonscreen-detected colorectal cancer: a contemporaneous study.
Mansouri D; McMillan DC; McIlveen E; Crighton EM; Morrison DS; Horgan PG
Colorectal Dis; 2016 Oct; 18(10):967-975. PubMed ID: 26859503
[TBL] [Abstract][Full Text] [Related]
65. New trend in colorectal cancer in Germany: are young patients at increased risk for advanced colorectal cancer?
Ambe PC; Jansen S; Zirngibl H
World J Surg Oncol; 2017 Aug; 15(1):159. PubMed ID: 28835275
[TBL] [Abstract][Full Text] [Related]
66. The fecal occult blood test as a tool for improved outpatient qualification for colonoscopy. A single-center experience and 10-year follow-up survey.
Banaszkiewicz Z; Budzyński J; Tojek K; Jarmocik P; Frasz J; Mrozowski M; Świtoński M; Jawień A
Adv Med Sci; 2017 Mar; 62(1):171-176. PubMed ID: 28282604
[TBL] [Abstract][Full Text] [Related]
67. Differences in diagnostic activity in general practice and findings for individuals invited to the danish screening programme for colorectal cancer: a population-based cohort study.
Juul JS; Andersen B; Laurberg S; Carlsen AH; Olesen F; Vedsted P
Scand J Prim Health Care; 2018 Sep; 36(3):281-290. PubMed ID: 29929415
[TBL] [Abstract][Full Text] [Related]
68. Interval colorectal cancer rates after Hemoccult Sensa and survival by detection mode for individuals diagnosed with colorectal cancer in Winnipeg, Manitoba.
Decker KM; Nugent Z; Lambert P; Biswanger N; Singh H
PLoS One; 2018; 13(9):e0203321. PubMed ID: 30180176
[TBL] [Abstract][Full Text] [Related]
69. Colorectal cancer screening: yield of faecal occult blood testing.
Teoh ML; Puvan R; Cheah PY; Yuen Y
Asian Pac J Cancer Prev; 2010; 11(1):153-6. PubMed ID: 20593948
[TBL] [Abstract][Full Text] [Related]
70. Comparison of screen-detected and interval colorectal cancers in the Bowel Cancer Screening Programme.
Gill MD; Bramble MG; Rees CJ; Lee TJ; Bradburn DM; Mills SJ
Br J Cancer; 2012 Jul; 107(3):417-21. PubMed ID: 22782347
[TBL] [Abstract][Full Text] [Related]
71. Implementation of immunochemical faecal occult blood test in general practice: a study protocol using a cluster-randomised stepped-wedge design.
Juul JS; Bro F; Hornung N; Andersen BS; Laurberg S; Olesen F; Vedsted P
BMC Cancer; 2016 Jul; 16():445. PubMed ID: 27400657
[TBL] [Abstract][Full Text] [Related]
72. The impact of colorectal screening program on the detection of right-sided colorectal cancer. A 5-year cohort study in the Mantua District.
Asteria CR; Pucciarelli S; Gerard L; Mantovani N; Pagani M; Boccia L; Ricci P; Troiano L; Lucchini G; Pulica C
Int J Colorectal Dis; 2015 Dec; 30(12):1627-37. PubMed ID: 26255258
[TBL] [Abstract][Full Text] [Related]
73. Using serum placenta growth factor could improve the sensitivity of colorectal cancer screening in fecal occult blood negative population: A multicenter with independent cohort validation study.
Wei SC; Tsao PN; Wang YT; Lin BR; Wu DC; Tsai WS; Chen JS; Wong JM
Cancer Med; 2019 Jul; 8(7):3583-3591. PubMed ID: 31063258
[TBL] [Abstract][Full Text] [Related]
74. Screening or Symptoms? How Do We Detect Colorectal Cancer in an Equal Access Health Care System?
Hatch QM; Kniery KR; Johnson EK; Flores SA; Moeil DL; Thompson JJ; Maykel JA; Steele SR
J Gastrointest Surg; 2016 Feb; 20(2):431-8. PubMed ID: 26628071
[TBL] [Abstract][Full Text] [Related]
75. Colorectal cancer screening: a global overview of existing programmes.
Schreuders EH; Ruco A; Rabeneck L; Schoen RE; Sung JJ; Young GP; Kuipers EJ
Gut; 2015 Oct; 64(10):1637-49. PubMed ID: 26041752
[TBL] [Abstract][Full Text] [Related]
76. Survival in patients with colorectal cancer diagnosed by screening colonoscopy.
Friedrich K; Grüter L; Gotthardt D; Eisenbach C; Stremmel W; Scholl SG; Rex DK; Sieg A
Gastrointest Endosc; 2015 Jul; 82(1):133-7. PubMed ID: 25986151
[TBL] [Abstract][Full Text] [Related]
77. Interval colorectal cancer after colonoscopy.
Richter JM; Campbell EJ; Chung DC
Clin Colorectal Cancer; 2015 Mar; 14(1):46-51. PubMed ID: 25510180
[TBL] [Abstract][Full Text] [Related]
78. Prevention of advanced colorectal cancer by screening using the immunochemical faecal occult blood test: a case-control study.
Nakajima M; Saito H; Soma Y; Sobue T; Tanaka M; Munakata A
Br J Cancer; 2003 Jul; 89(1):23-8. PubMed ID: 12838295
[TBL] [Abstract][Full Text] [Related]
79. Performance analysis of a machine learning flagging system used to identify a group of individuals at a high risk for colorectal cancer.
Kinar Y; Akiva P; Choman E; Kariv R; Shalev V; Levin B; Narod SA; Goshen R
PLoS One; 2017; 12(2):e0171759. PubMed ID: 28182647
[TBL] [Abstract][Full Text] [Related]
80. Total colonoscopy detects early colorectal cancer more frequently than advanced colorectal cancer in patients with fecal occult blood.
Ozaki T; Tokunaga A; Chihara N; Yoshino M; Bou H; Ogata M; Watanabe M; Suzuki H; Uchida E
J Nippon Med Sch; 2010 Aug; 77(4):195-203. PubMed ID: 20818137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
